Kalaris Therapeutics (KLRS) Enterprise Value (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Enterprise Value of -$167.7 million for Q1 2026, down 66.09% year-over-year from -$494.4 million in Q1 2025, and down 42.13% quarter-over-quarter from -$118.0 million in Q4 2025.
Kalaris Therapeutics (KLRS) Enterprise Value (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$167.7 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 66.09% year-over-year to -$167.7 million; the TTM figure through Mar 2026 stood at -$167.7 million (down 66.09% YoY), while the FY2025 annual figure was -$118.0 million, down 11592.96% from the prior year.
- Enterprise Value for Q1 2026 stood at -$167.7 million, down from -$118.0 million in the prior quarter.
- The five-year high for Enterprise Value was -$1.0 million in Q4 2024, with the low at -$264.1 million in Q3 2022.
- The 5-year median for Enterprise Value is -$167.7 million (2026), against an average of -$136.9 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 99.45% in 2024, then sank 11592.96% in 2025.
- Kalaris Therapeutics' Enterprise Value stood at -$233.8 million in 2022, then climbed by 21.32% to -$183.9 million in 2023, then surged by 99.45% to -$1.0 million in 2024, then tumbled by 11592.96% to -$118.0 million in 2025, then slumped by 42.13% to -$167.7 million in 2026.
- Business Quant data shows KLRS's Enterprise Value at -$167.7 million in Q1 2026, -$118.0 million in Q4 2025, and -$34.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -143.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -143.87 Mn |
| Mar 31, 2026 | -167.69 Mn |
| Dec 31, 2025 | -117.98 Mn |
| Sep 30, 2025 | -34.69 Mn |
| Jun 30, 2025 | -88.40 Mn |
| Mar 31, 2025 | -100.97 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | -6.91 Mn |
| Jun 30, 2024 | -31.11 Mn |
| Mar 31, 2024 | -59.72 Mn |
| Dec 31, 2023 | -183.94 Mn |
| Sep 30, 2023 | -213.32 Mn |
| Jun 30, 2023 | -246.54 Mn |
| Mar 31, 2023 | -202.57 Mn |
| Dec 31, 2022 | -233.80 Mn |
| Sep 30, 2022 | -264.11 Mn |
| Jun 30, 2022 | -172.67 Mn |
| Mar 31, 2022 | -201.38 Mn |
| Dec 31, 2021 | -248.12 Mn |
| Sep 30, 2021 | -275.84 Mn |